首页 > 最新文献

Current Opinion in Ophthalmology最新文献

英文 中文
Diversity, equity and inclusion in ophthalmology. 眼科的多样性、公平性和包容性。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000970
Ugochi T Aguwa, Basil K Williams, Fasika A Woreta

Purpose of review: Diversity, equity and inclusion (DEI) initiatives in ophthalmology have received increased attention in recent years. This review will highlight disparities, barriers to workforce diversity, as well as current and future efforts to improve DEI in ophthalmology.

Recent findings: Racial, ethnic, socioeconomic and sex disparities exist in vision health and across many ophthalmology subspecialties. The pervasive disparities result from factors such as a lack of access to eye care. In addition, ophthalmology is one of the least diverse specialties at the resident and faculty level. The lack of diversity has also been documented in ophthalmology clinical trials, wherein participant demographics do not reflect the diversity of the U.S. population.

Summary: Addressing social determinants of health including racism and discrimination is necessary to promote equity in vision health. Diversifying the workforce and expanding the representation of marginalized groups in clinical research are also paramount. Supporting existing programmes and creating new ones focusing on improving workforce diversity and reducing eye care disparities are essential to ensure equity in vision health for all Americans.

综述目的:近年来,眼科的多样性、公平性和包容性(DEI)倡议受到越来越多的关注。这篇综述将强调差异,劳动力多样性的障碍,以及目前和未来的努力,以提高DEI在眼科。最近的研究发现:种族、民族、社会经济和性别差异存在于视力健康和许多眼科亚专科。这种普遍存在的差距是由于缺乏获得眼科护理的机会等因素造成的。此外,眼科是住院医师和教师水平上多样化程度最低的专业之一。缺乏多样性也被记录在眼科临床试验中,其中参与者的人口统计数据并不能反映美国人口的多样性。摘要:解决包括种族主义和歧视在内的健康社会决定因素是促进视力健康公平的必要条件。使劳动力多样化和扩大边缘化群体在临床研究中的代表性也至关重要。支持现有方案并创建新的方案,重点是改善劳动力多样性和缩小眼科保健差距,这对于确保所有美国人在视力健康方面的公平至关重要。
{"title":"Diversity, equity and inclusion in ophthalmology.","authors":"Ugochi T Aguwa,&nbsp;Basil K Williams,&nbsp;Fasika A Woreta","doi":"10.1097/ICU.0000000000000970","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000970","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diversity, equity and inclusion (DEI) initiatives in ophthalmology have received increased attention in recent years. This review will highlight disparities, barriers to workforce diversity, as well as current and future efforts to improve DEI in ophthalmology.</p><p><strong>Recent findings: </strong>Racial, ethnic, socioeconomic and sex disparities exist in vision health and across many ophthalmology subspecialties. The pervasive disparities result from factors such as a lack of access to eye care. In addition, ophthalmology is one of the least diverse specialties at the resident and faculty level. The lack of diversity has also been documented in ophthalmology clinical trials, wherein participant demographics do not reflect the diversity of the U.S. population.</p><p><strong>Summary: </strong>Addressing social determinants of health including racism and discrimination is necessary to promote equity in vision health. Diversifying the workforce and expanding the representation of marginalized groups in clinical research are also paramount. Supporting existing programmes and creating new ones focusing on improving workforce diversity and reducing eye care disparities are essential to ensure equity in vision health for all Americans.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10356455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Toward safer ophthalmic artificial intelligence via distributed validation on real-world data. 通过对真实世界数据的分布式验证,实现更安全的眼科人工智能。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000986
Siddharth Nath, Ehsan Rahimy, Ashley Kras, Edward Korot

Purpose of review: The current article provides an overview of the present approaches to algorithm validation, which are variable and largely self-determined, as well as solutions to address inadequacies.

Recent findings: In the last decade alone, numerous machine learning applications have been proposed for ophthalmic diagnosis or disease monitoring. Remarkably, of these, less than 15 have received regulatory approval for implementation into clinical practice. Although there exists a vast pool of structured and relatively clean datasets from which to develop and test algorithms in the computational 'laboratory', real-world validation remains key to allow for safe, equitable, and clinically reliable implementation. Bottlenecks in the validation process stem from a striking paucity of regulatory guidance surrounding safety and performance thresholds, lack of oversight on critical postdeployment monitoring and context-specific recalibration, and inherent complexities of heterogeneous disease states and clinical environments. Implementation of secure, third-party, unbiased, pre and postdeployment validation offers the potential to address existing shortfalls in the validation process.

Summary: Given the criticality of validation to the algorithm pipeline, there is an urgent need for developers, machine learning researchers, and end-user clinicians to devise a consensus approach, allowing for the rapid introduction of safe, equitable, and clinically valid machine learning implementations.

回顾的目的:本文概述了目前算法验证的方法,这些方法是可变的,很大程度上是自决定的,以及解决不足的解决方案。最近的发现:仅在过去十年中,就有许多机器学习应用于眼科诊断或疾病监测。值得注意的是,其中只有不到15项获得了监管部门的批准,可用于临床实践。尽管存在大量结构化且相对干净的数据集,可用于在计算“实验室”中开发和测试算法,但现实世界的验证仍然是实现安全、公平和临床可靠实施的关键。验证过程中的瓶颈源于围绕安全性和性能阈值的监管指导明显缺乏,对关键的部署后监测和针对具体情况的重新校准缺乏监督,以及异质性疾病状态和临床环境的固有复杂性。安全的、第三方的、无偏见的部署前和部署后验证的实现,为解决验证过程中存在的不足提供了可能。摘要:鉴于验证对算法管道的重要性,开发人员、机器学习研究人员和最终用户临床医生迫切需要设计一种共识方法,以允许快速引入安全、公平和临床有效的机器学习实施。
{"title":"Toward safer ophthalmic artificial intelligence via distributed validation on real-world data.","authors":"Siddharth Nath,&nbsp;Ehsan Rahimy,&nbsp;Ashley Kras,&nbsp;Edward Korot","doi":"10.1097/ICU.0000000000000986","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000986","url":null,"abstract":"<p><strong>Purpose of review: </strong>The current article provides an overview of the present approaches to algorithm validation, which are variable and largely self-determined, as well as solutions to address inadequacies.</p><p><strong>Recent findings: </strong>In the last decade alone, numerous machine learning applications have been proposed for ophthalmic diagnosis or disease monitoring. Remarkably, of these, less than 15 have received regulatory approval for implementation into clinical practice. Although there exists a vast pool of structured and relatively clean datasets from which to develop and test algorithms in the computational 'laboratory', real-world validation remains key to allow for safe, equitable, and clinically reliable implementation. Bottlenecks in the validation process stem from a striking paucity of regulatory guidance surrounding safety and performance thresholds, lack of oversight on critical postdeployment monitoring and context-specific recalibration, and inherent complexities of heterogeneous disease states and clinical environments. Implementation of secure, third-party, unbiased, pre and postdeployment validation offers the potential to address existing shortfalls in the validation process.</p><p><strong>Summary: </strong>Given the criticality of validation to the algorithm pipeline, there is an urgent need for developers, machine learning researchers, and end-user clinicians to devise a consensus approach, allowing for the rapid introduction of safe, equitable, and clinically valid machine learning implementations.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10039563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence enabled smart digital eye wearables. 人工智能支持智能数字眼可穿戴设备。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000985
Narrendar RaviChandran, Zhen Ling Teo, Daniel S W Ting

Purpose of review: Smart eyewear is a head-worn wearable device that is evolving as the next phase of ubiquitous wearables. Although their applications in healthcare are being explored, they have the potential to revolutionize teleophthalmology care. This review highlights their applications in ophthalmology care and discusses future scope.

Recent findings: Smart eyewear equips advanced sensors, optical displays, and processing capabilities in a wearable form factor. Rapid technological developments and the integration of artificial intelligence are expanding their reach from consumer space to healthcare applications. This review systematically presents their applications in treating and managing eye-related conditions. This includes remote assessments, real-time monitoring, telehealth consultations, and the facilitation of personalized interventions. They also serve as low-vision assistive devices to help visually impaired, and can aid physicians with operational and surgical tasks.

Summary: Wearables such as smart eyewear collects rich, continuous, objective, individual-specific data, which is difficult to obtain in a clinical setting. By leveraging sophisticated data processing and artificial intelligence based algorithms, these data can identify at-risk patients, recognize behavioral patterns, and make timely interventions. They promise cost-effective and personalized treatment for vision impairments in an effort to mitigate the global burden of eye-related conditions and aging.

回顾目的:智能眼镜是一种头戴式可穿戴设备,正在发展成为无处不在的可穿戴设备的下一个阶段。虽然它们在医疗保健方面的应用还在探索中,但它们有可能彻底改变远端眼科护理。本文综述了它们在眼科护理中的应用,并讨论了未来的应用范围。最新发现:智能眼镜配备了先进的传感器、光学显示器和可穿戴形式的处理能力。快速的技术发展和人工智能的集成正在将其范围从消费领域扩展到医疗保健应用领域。这篇综述系统地介绍了它们在治疗和管理眼部相关疾病中的应用。这包括远程评估、实时监测、远程保健咨询和促进个性化干预。它们还可以作为低视力辅助设备来帮助视障人士,并可以帮助医生完成手术和手术任务。摘要:智能眼镜等可穿戴设备收集丰富、连续、客观、个性化的数据,这些数据在临床环境中很难获得。通过利用复杂的数据处理和基于人工智能的算法,这些数据可以识别高危患者,识别行为模式,并及时采取干预措施。他们承诺为视力障碍提供具有成本效益和个性化的治疗,以减轻与眼睛有关的疾病和衰老的全球负担。
{"title":"Artificial intelligence enabled smart digital eye wearables.","authors":"Narrendar RaviChandran,&nbsp;Zhen Ling Teo,&nbsp;Daniel S W Ting","doi":"10.1097/ICU.0000000000000985","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000985","url":null,"abstract":"<p><strong>Purpose of review: </strong>Smart eyewear is a head-worn wearable device that is evolving as the next phase of ubiquitous wearables. Although their applications in healthcare are being explored, they have the potential to revolutionize teleophthalmology care. This review highlights their applications in ophthalmology care and discusses future scope.</p><p><strong>Recent findings: </strong>Smart eyewear equips advanced sensors, optical displays, and processing capabilities in a wearable form factor. Rapid technological developments and the integration of artificial intelligence are expanding their reach from consumer space to healthcare applications. This review systematically presents their applications in treating and managing eye-related conditions. This includes remote assessments, real-time monitoring, telehealth consultations, and the facilitation of personalized interventions. They also serve as low-vision assistive devices to help visually impaired, and can aid physicians with operational and surgical tasks.</p><p><strong>Summary: </strong>Wearables such as smart eyewear collects rich, continuous, objective, individual-specific data, which is difficult to obtain in a clinical setting. By leveraging sophisticated data processing and artificial intelligence based algorithms, these data can identify at-risk patients, recognize behavioral patterns, and make timely interventions. They promise cost-effective and personalized treatment for vision impairments in an effort to mitigate the global burden of eye-related conditions and aging.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10025853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gaps and future of human-centered artificial intelligence in ophthalmology: Future Vision Forum consensus statement. 以人为中心的人工智能在眼科中的差距和未来:未来视力论坛共识声明。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000984
Daniel Shu Wei Ting, Mark S Humayun, Suber S Huang

Purpose of review: The Future Vision Forum discussed the current state of Human Centered Computing and the future of data collection, curation, and collation in ophthalmology. Although the uptake of electronic health record (EHR) systems and the digitization of healthcare data is encouraging, there are still barriers to implementing a specialty-wide clinical trial database. The article identifies several critical opportunities, including the need for standardization of image metadata and data, the establishment of a centralized trial database, incentives for clinicians and trial sponsors to participate, and resolving ethical concerns surrounding data ownership.

Findings: Recommendations to overcome these challenges include the standardization of image metadata using the Digital Imaging and Communications in Medicine (DICOM) guidelines, the establishment of a centralized trial database that uses federated learning (FL), and the use of FL to facilitate cross-institutional collaboration for rare diseases. Forum faculty suggests incentives will accelerate artificial intelligence, digital innovation projects, and data sharing agreements to empower patients to release their data.

Summary: A specialty-wide clinical trial database could provide invaluable insights into the natural history of disease, pathophysiology, why trials fail, and improve future clinical trial design. However, overcoming the barriers to implementation will require continued discussion, collaboration, and collective action from stakeholders across the ophthalmology community.

回顾目的:未来愿景论坛讨论了以人为中心的计算的现状以及眼科数据收集、管理和整理的未来。尽管电子健康记录(EHR)系统和医疗数据数字化的采用令人鼓舞,但在实施全专业临床试验数据库方面仍存在障碍。本文确定了几个关键机遇,包括对图像元数据和数据标准化的需求,建立一个集中的试验数据库,激励临床医生和试验发起人参与,以及解决有关数据所有权的伦理问题。研究结果:克服这些挑战的建议包括使用医学数字成像和通信(DICOM)指南对图像元数据进行标准化,建立使用联邦学习(FL)的集中试验数据库,以及使用FL促进罕见病的跨机构合作。论坛教员表示,激励措施将加速人工智能、数字创新项目和数据共享协议的发展,从而使患者能够发布自己的数据。摘要:一个专业范围的临床试验数据库可以为疾病的自然史、病理生理学、试验失败的原因提供宝贵的见解,并改进未来的临床试验设计。然而,克服实施的障碍需要整个眼科社区利益相关者的持续讨论、合作和集体行动。
{"title":"Gaps and future of human-centered artificial intelligence in ophthalmology: Future Vision Forum consensus statement.","authors":"Daniel Shu Wei Ting,&nbsp;Mark S Humayun,&nbsp;Suber S Huang","doi":"10.1097/ICU.0000000000000984","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000984","url":null,"abstract":"<p><strong>Purpose of review: </strong>The Future Vision Forum discussed the current state of Human Centered Computing and the future of data collection, curation, and collation in ophthalmology. Although the uptake of electronic health record (EHR) systems and the digitization of healthcare data is encouraging, there are still barriers to implementing a specialty-wide clinical trial database. The article identifies several critical opportunities, including the need for standardization of image metadata and data, the establishment of a centralized trial database, incentives for clinicians and trial sponsors to participate, and resolving ethical concerns surrounding data ownership.</p><p><strong>Findings: </strong>Recommendations to overcome these challenges include the standardization of image metadata using the Digital Imaging and Communications in Medicine (DICOM) guidelines, the establishment of a centralized trial database that uses federated learning (FL), and the use of FL to facilitate cross-institutional collaboration for rare diseases. Forum faculty suggests incentives will accelerate artificial intelligence, digital innovation projects, and data sharing agreements to empower patients to release their data.</p><p><strong>Summary: </strong>A specialty-wide clinical trial database could provide invaluable insights into the natural history of disease, pathophysiology, why trials fail, and improve future clinical trial design. However, overcoming the barriers to implementation will require continued discussion, collaboration, and collective action from stakeholders across the ophthalmology community.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10338591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alternative career paths for ophthalmologists. 眼科医生可选择的职业道路。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000975
Natalia F Callaway, Emmett T Cunningham

Purpose: Traditionally, ophthalmologists complete training and then choose a clinical care setting. The skills required to become an ophthalmologist can be applied to a variety of alternative career paths within and beyond healthcare. Not unexpectedly, therefore, there is a growing trend for ophthalmologists to explore alternative career paths in both healthcare and the life science industry more broadly. In this invited editorial, we summarize the more commonly considered 'alternative career paths,' and provide personal perspectives that have helped us and others when weighing such options.

Recent findings: Prior to pursuing an alternative career path, it is important to reflect on one's motivations and goals. A number of alternative careers paths are available, and the choice of when and what to pursue is both personal and personalizable. While it can be difficult to know a priori whether and to what extent a given path will be both enjoyable and rewarding, insights and advice from those who have walked that path before you can be invaluable. We review the more common paths of administrative leadership, entrepreneurship and innovation, product development, healthcare policy, nonprofit organizations, and investing, noting that these are just examples of the many options currently available.

Summary: Ophthalmologists should feel empowered to design a career that is both purposeful and personally meaningful, as this will result ultimately in the greatest happiness and fulfillment. There is a world of opportunity available to those who are willing to explore and create their own path.

目的:传统上,眼科医生完成培训,然后选择临床护理设置。成为眼科医生所需的技能可以应用于医疗保健内外的各种替代职业道路。因此,不出所料,眼科医生在医疗保健和生命科学行业更广泛地探索其他职业道路的趋势日益增长。在这篇应邀发表的社论中,我们总结了更常见的“可选择的职业道路”,并提供了一些个人观点,帮助我们和其他人在权衡这些选择时有所帮助。最近的研究发现:在选择另一条职业道路之前,反思自己的动机和目标是很重要的。有许多可供选择的职业道路,选择什么时候从事什么职业是个人的,也是可个性化的。虽然很难先验地知道一条既定的道路是否既有趣又有回报,以及在多大程度上既有趣又有回报,但在你之前走过这条道路的人的见解和建议是无价的。我们回顾了行政领导、创业和创新、产品开发、医疗保健政策、非营利组织和投资等更常见的途径,注意到这些只是目前可用的许多选择的示例。总结:眼科医生应该感到有能力设计一个既有目的又对个人有意义的职业,因为这最终会带来最大的幸福和满足感。对于那些愿意探索和创造自己道路的人来说,世界上充满了机会。
{"title":"Alternative career paths for ophthalmologists.","authors":"Natalia F Callaway,&nbsp;Emmett T Cunningham","doi":"10.1097/ICU.0000000000000975","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000975","url":null,"abstract":"<p><strong>Purpose: </strong>Traditionally, ophthalmologists complete training and then choose a clinical care setting. The skills required to become an ophthalmologist can be applied to a variety of alternative career paths within and beyond healthcare. Not unexpectedly, therefore, there is a growing trend for ophthalmologists to explore alternative career paths in both healthcare and the life science industry more broadly. In this invited editorial, we summarize the more commonly considered 'alternative career paths,' and provide personal perspectives that have helped us and others when weighing such options.</p><p><strong>Recent findings: </strong>Prior to pursuing an alternative career path, it is important to reflect on one's motivations and goals. A number of alternative careers paths are available, and the choice of when and what to pursue is both personal and personalizable. While it can be difficult to know a priori whether and to what extent a given path will be both enjoyable and rewarding, insights and advice from those who have walked that path before you can be invaluable. We review the more common paths of administrative leadership, entrepreneurship and innovation, product development, healthcare policy, nonprofit organizations, and investing, noting that these are just examples of the many options currently available.</p><p><strong>Summary: </strong>Ophthalmologists should feel empowered to design a career that is both purposeful and personally meaningful, as this will result ultimately in the greatest happiness and fulfillment. There is a world of opportunity available to those who are willing to explore and create their own path.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10357941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Artificial intelligence for home monitoring devices. 人工智能家庭监控设备。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000981
Tiarnan D L Keenan, Anat Loewenstein

Purpose of review: Home monitoring in ophthalmology is appropriate for disease stages requiring frequent monitoring or rapid intervention, for example, neovascular age-related macular degeneration (AMD) and glaucoma, where the balance between frequent hospital attendance versus risk of late detection is a constant challenge. Artificial intelligence approaches are well suited to address some challenges of home monitoring.

Recent findings: Ophthalmic data collected at home have included functional (e.g. perimetry), biometric (e.g. intraocular pressure), and imaging [e.g. optical coherence tomography (OCT)] data. Potential advantages include early detection/intervention, convenience, cost, and visual outcomes. Artificial intelligence can assist with home monitoring workflows by handling large data volumes from frequent testing, compensating for test quality, and extracting useful metrics from complex data. Important use cases include machine learning applied to hyperacuity self-testing for detecting neovascular AMD and deep learning applied to OCT data for quantifying retinal fluid.

Summary: Home monitoring of health conditions is useful for chronic diseases requiring rapid intervention or frequent data sampling to decrease risk of irreversible vision loss. Artificial intelligence may facilitate accurate, frequent, large-scale home monitoring, if algorithms are integrated safely into workflows. Clinical trials and economic evaluations are important to demonstrate the value of artificial intelligence-based home monitoring, towards improved visual outcomes.

综述目的:眼科家庭监测适用于需要频繁监测或快速干预的疾病阶段,例如,新生血管性年龄相关性黄斑变性(AMD)和青光眼,在这些疾病阶段,频繁住院与晚期发现风险之间的平衡是一个持续的挑战。人工智能方法非常适合解决家庭监控的一些挑战。最近的发现:在家里收集的眼科数据包括功能(如视野测量)、生物特征(如眼压)和成像(如光学相干断层扫描(OCT))数据。潜在的优势包括早期检测/干预、方便、成本和视觉效果。人工智能可以通过处理来自频繁测试的大量数据、补偿测试质量以及从复杂数据中提取有用的度量来帮助家庭监控工作流程。重要的用例包括用于检测新生血管性AMD的超锐自检的机器学习和用于量化视网膜液的OCT数据的深度学习。摘要:家庭健康状况监测对于需要快速干预或频繁数据采样以降低不可逆视力丧失风险的慢性疾病是有用的。如果将算法安全地集成到工作流程中,人工智能可能会促进准确、频繁、大规模的家庭监控。临床试验和经济评估对于证明基于人工智能的家庭监控在改善视觉效果方面的价值非常重要。
{"title":"Artificial intelligence for home monitoring devices.","authors":"Tiarnan D L Keenan,&nbsp;Anat Loewenstein","doi":"10.1097/ICU.0000000000000981","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000981","url":null,"abstract":"<p><strong>Purpose of review: </strong>Home monitoring in ophthalmology is appropriate for disease stages requiring frequent monitoring or rapid intervention, for example, neovascular age-related macular degeneration (AMD) and glaucoma, where the balance between frequent hospital attendance versus risk of late detection is a constant challenge. Artificial intelligence approaches are well suited to address some challenges of home monitoring.</p><p><strong>Recent findings: </strong>Ophthalmic data collected at home have included functional (e.g. perimetry), biometric (e.g. intraocular pressure), and imaging [e.g. optical coherence tomography (OCT)] data. Potential advantages include early detection/intervention, convenience, cost, and visual outcomes. Artificial intelligence can assist with home monitoring workflows by handling large data volumes from frequent testing, compensating for test quality, and extracting useful metrics from complex data. Important use cases include machine learning applied to hyperacuity self-testing for detecting neovascular AMD and deep learning applied to OCT data for quantifying retinal fluid.</p><p><strong>Summary: </strong>Home monitoring of health conditions is useful for chronic diseases requiring rapid intervention or frequent data sampling to decrease risk of irreversible vision loss. Artificial intelligence may facilitate accurate, frequent, large-scale home monitoring, if algorithms are integrated safely into workflows. Clinical trials and economic evaluations are important to demonstrate the value of artificial intelligence-based home monitoring, towards improved visual outcomes.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9972489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of physician extenders: more regulation is necessary before full integration into practice. 医师扩展者的作用:在完全融入实践之前,需要更多的监管。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000971
Saira Khanna, Geoffrey G Emerson, Gaurav K Shah

Purpose of review: To discuss the drawbacks and propose recommendations for integrating physician extenders in ophthalmologic practice.

Recent findings: In this article, the role of utilizing physician extenders in ophthalmology is discussed. A role for physician extenders has been suggested as more and more patients will require ophthalmologic care.

Summary: Guidance is needed on how to best integrate physician extenders into eye care. However, quality of care is of the highest importance, and unless there is reliable and consistent training of extenders, using physician extenders to administer invasive procedures (e.g., intravitreal injection) should be avoided due to safety concerns.

综述的目的:讨论在眼科实践中整合医师扩展器的弊端并提出建议。在本文中,利用医师扩展器在眼科的作用进行了讨论。随着越来越多的患者需要眼科护理,医生扩展者的作用已被提出。总结:需要指导如何最好地将医师扩展器整合到眼科护理中。然而,护理质量是最重要的,除非有可靠和一致的扩展器培训,否则出于安全考虑,应避免使用医师扩展器来实施侵入性手术(例如,玻璃体内注射)。
{"title":"Role of physician extenders: more regulation is necessary before full integration into practice.","authors":"Saira Khanna,&nbsp;Geoffrey G Emerson,&nbsp;Gaurav K Shah","doi":"10.1097/ICU.0000000000000971","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000971","url":null,"abstract":"<p><strong>Purpose of review: </strong>To discuss the drawbacks and propose recommendations for integrating physician extenders in ophthalmologic practice.</p><p><strong>Recent findings: </strong>In this article, the role of utilizing physician extenders in ophthalmology is discussed. A role for physician extenders has been suggested as more and more patients will require ophthalmologic care.</p><p><strong>Summary: </strong>Guidance is needed on how to best integrate physician extenders into eye care. However, quality of care is of the highest importance, and unless there is reliable and consistent training of extenders, using physician extenders to administer invasive procedures (e.g., intravitreal injection) should be avoided due to safety concerns.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10356454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus. 人工智能对视网膜疾病管理的影响:视觉学会视网膜专家共识。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000980
Carla Danese, Aditya U Kale, Tariq Aslam, Jane Barratt, Yu-Bai Chou, Bora Eldem, Nicole Eter, Richard Gale, Jean-François Korobelnik, Igor Kozak, Paolo Lanzetta, Xiaorong Li, Xiaoxin Li, Anat Loewenstein, Paisan Ruamviboonsuk, Taiji Sakamoto, Daniel S W Ting, Peter van Wijngaarden, Sebastian M Waldstein, David Wong, Lihteh Wu, Miguel A Zapata, Javier Zarranz-Ventura

Purpose of review: The aim of this review is to define the "state-of-the-art" in artificial intelligence (AI)-enabled devices that support the management of retinal conditions and to provide Vision Academy recommendations on the topic.

Recent findings: Most of the AI models described in the literature have not been approved for disease management purposes by regulatory authorities. These new technologies are promising as they may be able to provide personalized treatments as well as a personalized risk score for various retinal diseases. However, several issues still need to be addressed, such as the lack of a common regulatory pathway and a lack of clarity regarding the applicability of AI-enabled medical devices in different populations.

Summary: It is likely that current clinical practice will need to change following the application of AI-enabled medical devices. These devices are likely to have an impact on the management of retinal disease. However, a consensus needs to be reached to ensure they are safe and effective for the overall population.

综述的目的:本综述的目的是定义支持视网膜疾病管理的人工智能(AI)启用设备的“最先进”技术,并就该主题提供视觉学会的建议。最近的发现:文献中描述的大多数人工智能模型尚未被监管机构批准用于疾病管理目的。这些新技术很有前景,因为它们可以为各种视网膜疾病提供个性化治疗和个性化风险评分。然而,仍有几个问题需要解决,例如缺乏共同的监管途径,以及人工智能医疗设备在不同人群中的适用性缺乏明确性。摘要:随着人工智能医疗设备的应用,目前的临床实践可能需要改变。这些设备可能对视网膜疾病的治疗产生影响。然而,需要达成共识,以确保它们对全体人口是安全和有效的。
{"title":"The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus.","authors":"Carla Danese,&nbsp;Aditya U Kale,&nbsp;Tariq Aslam,&nbsp;Jane Barratt,&nbsp;Yu-Bai Chou,&nbsp;Bora Eldem,&nbsp;Nicole Eter,&nbsp;Richard Gale,&nbsp;Jean-François Korobelnik,&nbsp;Igor Kozak,&nbsp;Paolo Lanzetta,&nbsp;Xiaorong Li,&nbsp;Xiaoxin Li,&nbsp;Anat Loewenstein,&nbsp;Paisan Ruamviboonsuk,&nbsp;Taiji Sakamoto,&nbsp;Daniel S W Ting,&nbsp;Peter van Wijngaarden,&nbsp;Sebastian M Waldstein,&nbsp;David Wong,&nbsp;Lihteh Wu,&nbsp;Miguel A Zapata,&nbsp;Javier Zarranz-Ventura","doi":"10.1097/ICU.0000000000000980","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000980","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this review is to define the \"state-of-the-art\" in artificial intelligence (AI)-enabled devices that support the management of retinal conditions and to provide Vision Academy recommendations on the topic.</p><p><strong>Recent findings: </strong>Most of the AI models described in the literature have not been approved for disease management purposes by regulatory authorities. These new technologies are promising as they may be able to provide personalized treatments as well as a personalized risk score for various retinal diseases. However, several issues still need to be addressed, such as the lack of a common regulatory pathway and a lack of clarity regarding the applicability of AI-enabled medical devices in different populations.</p><p><strong>Summary: </strong>It is likely that current clinical practice will need to change following the application of AI-enabled medical devices. These devices are likely to have an impact on the management of retinal disease. However, a consensus needs to be reached to ensure they are safe and effective for the overall population.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10356459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges and controversies in ophthalmology in 2023. 2023年眼科面临的挑战与争议。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000969
Christina Y Weng, Jayanth Sridhar
{"title":"Challenges and controversies in ophthalmology in 2023.","authors":"Christina Y Weng,&nbsp;Jayanth Sridhar","doi":"10.1097/ICU.0000000000000969","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000969","url":null,"abstract":"","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10346329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence for ocular oncology. 眼部肿瘤的人工智能。
IF 3.7 2区 医学 Q1 Medicine Pub Date : 2023-09-01 DOI: 10.1097/ICU.0000000000000982
Neslihan Dilruba Koseoglu, Zélia Maria Corrêa, T Y Alvin Liu

Purpose of review: The aim of this article is to provide an update on the latest applications of deep learning (DL) and classical machine learning (ML) techniques to the detection and prognostication of intraocular and ocular surface malignancies.

Recent findings: Most recent studies focused on using DL and classical ML techniques for prognostication purposes in patients with uveal melanoma (UM).

Summary: DL has emerged as the leading ML technique for prognostication in ocular oncological conditions, particularly in UM. However, the application of DL may be limited by the relatively rarity of these conditions.

综述目的:本文的目的是提供深度学习(DL)和经典机器学习(ML)技术在眼内和眼表恶性肿瘤的检测和预测中的最新应用。最新发现:最近的研究主要集中在使用DL和经典ML技术来预测葡萄膜黑色素瘤(UM)患者的预后。总结:DL已经成为预测眼部肿瘤的主要ML技术,特别是在UM中。然而,深度学习的应用可能会受到这些条件相对罕见的限制。
{"title":"Artificial intelligence for ocular oncology.","authors":"Neslihan Dilruba Koseoglu,&nbsp;Zélia Maria Corrêa,&nbsp;T Y Alvin Liu","doi":"10.1097/ICU.0000000000000982","DOIUrl":"https://doi.org/10.1097/ICU.0000000000000982","url":null,"abstract":"<p><strong>Purpose of review: </strong>The aim of this article is to provide an update on the latest applications of deep learning (DL) and classical machine learning (ML) techniques to the detection and prognostication of intraocular and ocular surface malignancies.</p><p><strong>Recent findings: </strong>Most recent studies focused on using DL and classical ML techniques for prognostication purposes in patients with uveal melanoma (UM).</p><p><strong>Summary: </strong>DL has emerged as the leading ML technique for prognostication in ocular oncological conditions, particularly in UM. However, the application of DL may be limited by the relatively rarity of these conditions.</p>","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/66/06/cooph-34-437.PMC10399931.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10356461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Opinion in Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1